


PHARMACEUTICAL 2020



Deciphera Pharmaceuticals Inc. Rank 109 of 362





PHARMACEUTICAL 2020



Deciphera Pharmaceuticals Inc. Rank 109 of 362

The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 241% points. The greatest weakness of Deciphera Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 252% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	593,408
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,038
Liabilities, Non-Current	15,904
Other Assets	22,668
Other Compr. Net Income	111
Other Expenses	0
Other Liabilities	0
Other Net Income	8,470
Property and Equipment	6,333
Research and Development	157,610
Revenues	25,000
Selling, General and Administrative Expense	68,116

Output Variable	Value in 1000 USD
Assets	622,409
Liabilities	75,942
Expenses	225,726
Stockholders Equity	546,467
Net Income	-192,256
Comprehensive Net Income	-192,200
Economic Capital Ratio	-51%